PTN and neoplasm: Disrupting the PTN–PTPRZ1 signalling by shRNA or the antibody blockade against PTPRZ1 largely abrogates the tumour-supportive effects of PTN and suppresses GBM growth driven by the tumour-initiating GSCs.